Perimenopause period and menopause: cardiovascular and metabolic risks

Authors

DOI:

https://doi.org/10.14739/2310-1210.2024.5.303438

Keywords:

perimenopause, menopause, cardiovascular risk, metabolic risk, cardiovascular diseases, metabolic syndrome, osteoporosis, treatment

Abstract

The number of mature and elderly women is increasing all over the world. According to the World Health Organization, in most countries of the world, the life expectancy of women after the age of 50 ranges from 27 to 32 years. Thus, approximately one third of a woman’s life is lived after menopause.

Aim. To analyze and summarize scientific data on cardiovascular and metabolic risks in perimenopausal and menopausal women based on the use of scientometric databases.

Menopause should be considered as a risk factor for the development of cardiovascular diseases (CVDs), which triggers a whole cascade of pathological changes in a woman’s body, including the development of arterial hypertension, dyslipidemia, abdominal obesity, insulin resistance, an increased sympathoadrenal tone, endothelial function disorders, and inflammatory vascular reactions. CVD is known to be the leading cause of death among postmenopausal women associated with the loss of estrogenic protective effect on the cardiovascular system. Women with premature menopause have a 33 % higher risk of heart failure and a 9 % higher risk of atrial fibrillation.

Metabolic syndrome is more common in postmenopausal women than in premenopausal women. It is defined as a cluster of disorders characterized by impaired glucose metabolism, high blood pressure, central obesity, low high-density lipoprotein cholesterol, high low-density lipoprotein cholesterol and triglycerides. It is the activity of low-density lipoproteins and an increase in the level of triglycerides that have serious consequences in the etiology of cardiovascular diseases and the development of atherosclerosis.

Osteoporosis ranks fourth among non-communicable diseases after CVD, cancer and diabetes. Estrogen deficiency during menopause results in increased osteoclast resorptive activity, while osteoblast function remains relatively constant, ultimately resulting in bone loss. In the first postmenopausal years, a woman can lose up to 9–35 % of bone mass, postmenopausal osteoporosis affects between one third to a half of all women.

Conclusions. Menopause is a difficult period in a woman’s life, during which the risk of developing cardiovascular diseases and metabolic disorders increases, as well as almost all somatic diseases are exacerbated. Therefore, proper assessment of such risks is mandatory to improve long-term CVD outcomes. Given this, it is the interdisciplinary interaction that is central to early detection of symptoms and diagnosis of climacteric disorders for the timely prescription of treatment. Physicians working with this contingent of women should apply a comprehensive approach to health care and quality of life preservation during the menopause transition, menopause and postmenopause.

Author Biographies

V. H. Siusiuka, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Obstetrics and Gynecology

V. A. Vizir, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, DSc, Professor of the Department of Internal Medicine No. 2

M. Yu. Serhienko, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, Associate Professor of the Department of Obstetrics and Gynecology

O. V. Demidenko, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, Associate Professor of the Department of Obstetrics and Gynecology

O. V. Deinichenko, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, Associate Professor of the Department of Obstetrics and Gynecology

References

  1. Lumsden MA. The NICE Guideline - Menopause: diagnosis and management. Climacteric. 2016;19(5):426-9. doi: https://doi.org/10.1080/13697137.2016.1222483
  2. Dubossarska ZM, Dubossarska YA. [Features of menopause management as an aging prevention (review article)]. Scientific digest of association of obstetricians and gynecologists of Ukraine. 2023;1(51):20-5. Ukrainian. doi: https://doi.org/10.35278/2664-0767.1(51).2023.294839
  3. Ko SH, Kim HS. Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women. Nutrients. 2020;12(1):202. doi: https://doi.org/10.3390/nu12010202
  4. Pirohova VI. [Menopause and osteoporosis. The role of the gynecologist in solving the problem. According to the materials of the conference]. Medychni aspekty zdorovia zhinky. 2021;0(5-6):36-8. Ukrainian. Available from: https://mazg.com.ua/uploads/issues/2021/5-6(140-141)/mazg21_5-6_36-39.pdf
  5. Ministry of Health of Ukraine. [Evidence-Based Clinical Guidelines Menopausal Disorders and Other Perimenopausal Disorders] [Internet]. 2022 [cited 2024 Apr 1]. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2022/06/2022_01_13_kn_menopauz_rozlady.pdf
  6. Lega IC, Fine A, Antoniades ML, Jacobson M. Approche pragmatique à la prise en charge de la ménopause. CMAJ. 2023;195(29):E989-E995. French. doi: https://doi.org/10.1503/cmaj.221438-f
  7. Ministry of Health of Ukraine. [Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care "Menopausal disorders and other disorders in the perimenopausal period"]. Order dated 2022 Jun 17, No. 1039. [Internet]. 2022 [cited 2024 Apr 1]. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2022/06/37474-dn_1039_17_06_2022_dod.pdf
  8. Barna OM, Yefimenko OO, Kosei NV, Mishchenko LA, Pedachenko NY, Tatarchuk TF. [Health care for women in menopause. Clinical lecture for general practitioners – family doctors]. Reproductive Endocrinology. 2023;1(67):30-8. Ukrainian. https://doi.org/10.18370/2309-4117.2023.67.30-38
  9. Writing Group Members; Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;266133(4):e38-360. doi: https://doi.org/10.1161/CIR.0000000000000350
  10. Maas AH, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J. 2021;42(10):967-84. doi: https://doi.org/10.1093/eurheartj/ehaa1044
  11. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532. doi: https://doi.org/10.1161/CIR.0000000000000912
  12. Nair AR, Pillai AJ, Nair N. Cardiovascular Changes in Menopause. Curr Cardiol Rev. 2021;17(4):e230421187681. doi: https://doi.org/10.2174/1573403X16666201106141811
  13. Ryczkowska K, Adach W, Janikowski K, Banach M, Bielecka-Dabrowa A. Menopause and women's cardiovascular health: is it really an obvious relationship?. Arch Med Sci. 2022;19(2):458-66. doi: https://doi.org/10.5114/aoms/157308
  14. Shin J, Han K, Jung JH, Park HJ, Kim W, Huh Y, et al. Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study. Eur Heart J. 2022;43(40):4148-57. doi: https://doi.org/10.1093/eurheartj/ehac364
  15. Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019;4(11):e553-e564. doi: https://doi.org/10.1016/S2468-2667(19)30155-0
  16. Ueda K, Fukuma N, Adachi Y, Numata G, Tokiwa H, Toyoda M, et al. Sex Differences and Regulatory Actions of Estrogen in Cardiovascular System. Front Physiol. 2021;12:738218. doi: https://doi.org/10.3389/fphys.2021.738218
  17. Anagnostis P, Stevenson JC. Cardiovascular health and the menopause, metabolic health. Best Pract Res Clin Endocrinol Metab. 2024;38(1):101781. doi: https://doi.org/10.1016/j.beem.2023.101781
  18. Honigberg MC, Zekavat SM, Aragam K, Finneran P, Klarin D, Bhatt DL, et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA. 2019;322(24):2411-21. doi: https://doi.org/10.1001/jama.2019.19191
  19. Maas AH. Cardiovascular risk assessment in women: which women are suited for menopausal hormone therapy?. Climacteric. 2024;27(1):89-92. doi: https://doi.org/10.1080/13697137.2023.2259799
  20. Kamińska MS, Schneider-Matyka D, Rachubińska K, Panczyk M, Grochans E, Cybulska AM. Menopause Predisposes Women to Increased Risk of Cardiovascular Disease. J Clin Med. 2023;12(22):7058. doi: https://doi.org/10.3390/jcm12227058
  21. Lakhno IV, Podbeltseva YV, Kreknina VM. [Women in menopause and strategy Life еxtension]. Medychni aspekty zdorovia zhinky. 2021;0(3):1-4. Ukrainian. Available from: https://mazg.com.ua/uploads/issues/2021/3(138)/mazg21_3_YuF.pdf
  22. WHO. Obesity and Overweight [Internet]. WHO.int. 2021. Available from: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
  23. Perry A, Wang X, Goldberg R, Ross R, Jackson L. Androgenic sex steroids contribute to metabolic risk beyond intra-abdominal fat in overweight/obese black and white women. Obesity (Silver Spring). 2013;21(8):1618-24. doi: https://doi.org/10.1002/oby.20204
  24. Collins BC, Laakkonen EK, Lowe DA. Aging of the musculoskeletal system: How the loss of estrogen impacts muscle strength. Bone. 2019;123:137-44. doi: https://doi.org/10.1016/j.bone.2019.03.033
  25. Razmjou S, Abdulnour J, Bastard JP, ellahi S, Doucet É, Brochu M, et al. Body composition, cardiometabolic risk factors, physical activity, and inflammatory markers in premenopausal women after a 10-year follow-up: a MONET study. Menopause. 2018;25(1):89-97. doi: https://doi.org/10.1097/GME.0000000000000951
  26. Ebtekar F, Dalvand S, Gheshlagh RG. The prevalence of metabolic syndrome in postmenopausal women: A systematic review and meta-analysis in Iran. Diabetes Metab Syndr. 2018;12(6):955-960. doi: https://doi.org/10.1016/j.dsx.2018.06.002
  27. Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Yazdi D, et al. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020;219:70-7. doi: https://doi.org/10.1016/j.ahj.2019.10.014
  28. Dobiášová M. Atherogenic impact of lecithin-cholesterol acyltransferase and its relation to cholesterol esterification rate in HDL (FER(HDL)) and AIP [log(TG/HDL-C)] biomarkers: the butterfly effect?. Physiol Res. 2017;66(2):193-203. doi: https://doi.org/10.33549/physiolres.933621
  29. Thurston RC, Chang Y, Barinas-Mitchell E, Jennings JR, Landsittel DP, Santoro N, et al. Menopausal Hot Flashes and Carotid Intima Media Thickness Among Midlife Women. Stroke. 2016;47(12):2910-5. doi: https://doi.org/10.1161/STROKEAHA.116.014674
  30. Thurston RC, Aslanidou Vlachos HE, Derby CA, Jackson EA, Brooks MM, Matthews KA, et al. Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. J Am Heart Assoc. 2021;2,10(3):e017416. doi: https://doi.org/10.1161/JAHA.120.017416
  31. Zhu D, Chung HF, Dobson AJ, Pandeya N, Anderson DJ, Kuh D, et al. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am J Obstet Gynecol. 2020;223(6):898.e1-898.e16. doi: https://doi.org/10.1016/j.ajog.2020.06.039
  32. Gray KE, Katon JG, LeBlanc ES, Woods NF, Bastian LA, Reiber GE, et al. Vasomotor symptom characteristics: are they risk factors for incident diabetes? Menopause. 2018;25(5):520-30. doi: https://doi.org/10.1097/GME.0000000000001033
  33. Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, Meczekalski B, Zozulinska-Ziolkiewicz D, Jaremek JD, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6-10. doi: https://doi.org/10.1016/j.maturitas.2018.08.009
  34. Lambrinoudaki I, Paschou SA, Armeni E, Goulis DG. The interplay between diabetes mellitus and menopause: clinical implications. Nat Rev Endocrinol. 2022;18(10):608-22. doi: https://doi.org/10.1038/s41574-022-00708-0
  35. Paschou SA, Anagnostis P, Pavlou DI, Vryonidou A, Goulis DG, Lambrinoudaki I. Diabetes in Menopause: Risks and Management. Curr Vasc Pharmacol. 2019;17(6):556-63. doi: https://doi.org/10.2174/1570161116666180625124405
  36. Paschou SA, Marina LV, Spartalis E, Anagnostis P, Alexandrou A, Goulis DG, et al. Therapeutic strategies for type 2 diabetes mellitus in women after menopause. Maturitas. 2019;126:69-72. doi: https://doi.org/10.1016/j.maturitas.2019.05.003
  37. Kondratiuk V, Gorban N, Dzis N, Kondatiuk K, Dzuba G. [Women’s health and osteoporosis: a modern view on the problem (Literature review)]. Reproductive health of woman. 2023;0(3):83-9. Ukrainian. Available from: https://repro-health.com.ua/article/view/283898
  38. Na Z, Wei W, Xu Y, Li D, Yin B, Gu W. Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis. Open Life Sci. 2023;18(1):20220759. doi: https://doi.org/10.1515/biol-2022-0759
  39. Pouillès JM, Gosset A, Trémollieres F. Ménopause, traitement hormonal de ménopause et ostéoporose. RPC Les femmes ménopausées du CNGOF et du GEMVi [Menopause, menopause hormone therapy and osteoporosis. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. Gynecol Obstet Fertil Senol. 2021;49(5):420-37. doi: https://doi.org/10.1016/j.gofs.2021.03.015
  40. Grygorieva N, Kovalenko V, Коrzh М, Tatarchuk T, Dedukh N, Strafun S, et al. Guideline for diagnostic, prevention and treatment of postmenopausal osteoporosis. Pain, joints, spine. 2023;13(3):128-54:doi: https://doi.org/10.22141/pjs.13.3.2023.378
  41. Hill K. The demography of menopause. Maturitas. 1996;23(2):113-27. doi: https://doi.org/10.1016/0378-5122(95)00968-x
  42. [Treatment of osteoporosis in postmenopausal women. Expert position of the North American Menopause Society (NAMS, 2021)]. Medychni aspekty zdorovia zhinky. 2022;(3-4):24-32. Ukrainian. Available from: https://mazg.com.ua/ua/archive/2022/3-4%28144-145%29/pages-24-32/likuvannya-osteoporozu-u-zhinok-u-period-postmenopauzi
  43. Emmanuelle NE, Marie-Cécile V, Florence T, Jean-François A, Françoise L, Coralie F, et al. Critical Role of Estrogens on Bone Homeostasis in Both Male and Female: From Physiology to Medical Implications. Int J Mol Sci. 2021;22(4):1568. doi: https://doi.org/10.3390/ijms22041568
  44. Starrach T, Santl A, Seifert-Klauss VR. Perimenopausal Bone Loss Is Associated with Ovulatory Activity-Results of the PeKnO Study (Perimenopausal Bone Density and Ovulation). Diagnostics (Basel). 2022;12(2):305. doi: https://doi.org/10.3390/diagnostics12020305
  45. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-102. doi: https://doi.org/10.1007/s00198-021-05900-y
  46. Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, et al. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. Endocr Rev. 2019;40(4):1109-51. doi: https://doi.org/10.1210/er.2018-00126
  47. Degli Esposti L, Girardi A, Saragoni S, Sella S, Andretta M, Rossini M, et al. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk. Endocrine. 2019;64(2):367-77. doi: https://doi.org/10.1007/s12020-018-1824-9
  48. Holick MF. Calcium and vitamin D. Diagnostics and therapeutics. Clin Lab Med. 2000;20(3):569-90.
  49. Lee CJ, Kim SS, Suh WY, Kim JS, Jung JG, Yoon SJ, et al. The Effect of Education and Vitamin D Supplementation on the Achievement of Optimal Vitamin D Level in Korean Postmenopausal Women. J Bone Metab. 2019;26(3):193-9. doi: https://doi.org/10.11005/jbm.2019.26.3.193
  50. Branco JM, Smoraog DC, Bentes CM, Netto CC, Marinheiro LP. Association between vitamin D status and glycemic profile in postmenopausal women with type 2 diabetes. Diabetes Metab Syndr. 2019;13(3):1685-8. doi: https://doi.org/10.1016/j.dsx.2019.03.040
  51. Vitale SG, Caruso S, Rapisarda AM, Cianci S, Cianci A. Isoflavones, calcium, vitamin D and inulin improve quality of life, sexual function, body composition and metabolic parameters in menopausal women: result from a prospective, randomized, placebo-controlled, parallel-group study. Prz Menopauzalny. 2018;17(1):32-8. doi: https://doi.org/10.5114/pm.2018.73791
  52. Pradeep Y, Anand N. Cardiovacular Diseases MHT and Midlife Health. J Midlife Health. 2023;14(4):235-6. doi: https://doi.org/10.4103/jmh.jmh_18_24
  53. Prabakaran S, Schwartz A, Lundberg G. Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy: risks, benefits, and current guidelines for use. Ther Adv Endocrinol Metab. 2021;12:20420188211013917. doi: https://doi.org/10.1177/20420188211013917
  54. Resolution of the 4th international menopause expert forum. Reproductive Endocrinology. 2023;4(69):89-94. Ukrainian. doi: https://doi.org/10.18370/2309-4117.2023.69.2-6

Downloads

Additional Files

Published

2024-10-04

How to Cite

1.
Siusiuka VH, Vizir VA, Serhienko MY, Demidenko OV, Deinichenko OV. Perimenopause period and menopause: cardiovascular and metabolic risks. Zaporozhye Medical Journal [Internet]. 2024Oct.4 [cited 2026May16];26(5):424-9. Available from: https://zmj.zsmu.edu.ua/article/view/303438

Issue

Vol. 26 No. 5 (2024)

Section

Review

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons